Chr. Hansen Holding has completed the acquisition of UAS Laboratories following the satisfaction of all closing conditions.
With UAS Labs, Chr. Hansen further strengthens its microbial platform and Human Health business by moving into the highly attractive space of multi-species, high-potency blends and broadening its product offering and customer base.
Furthermore, Chr. Hansen is expanding its manufacturing footprint with two GMP facilities in the United States which will allow phasing of capex projects over the coming years and reduce enterprise risk.
Mauricio Graber, CEO of Chr. Hansen, said: "We will expand our probiotic offerings from strain to solution, gain access to new customer groups and move into new indication areas whilst staying true to our commitment to science and R&D. We are really excited to welcome the team from UAS Labs to the Chr. Hansen organization and will pursue a 'best of both' approach for the integration to create value for customers and shareholders. I am convinced that together we can truly shape the global probiotics market for the future."
Chr. Hansen will now begin the process of integrating UAS Labs. UAS Labs has 230 employees and is expected to generate revenues of around $85 million before synergies in 2020.
Acquiring UAS Labs is fully in line with Chr. Hansen's strategy and capital allocation framework of pursuing bolt-on acquisitions to strengthen its microbial platform.
